Abstract: Configuration bits are provided that configure PWM outputs of a processor incorporating a PWM module. The configuration bits cause the PWM module to put the PWM outputs into tri-state, active high or active low modes when the PWM module is inactive or when individual PWM outputs are not enabled. The configuration bits are stored in non-volatile memory and perform the configuration after power-up of the processor and after a reset when the PWM module is generally in an inactive state.

Abstract: A processor that has pulse width modulation generation circuitry that provides an improved ability to deal with the less than perfect switching characteristics of external switching devices that are connected to PWM hardware included in a processor. Complementary PWM output signals have dual deadtime delay in which the delay between the inactivation of the first signal and the activation of the second signal may be different than the delay between the inactivation of the second signal and the activation of the first signal. This provides an improved capability to deal with non-symmetric switching characteristics of the external switching devices, and the circuitry to which they are connected.

Abstract: The present invention relates generally to functional pathway configurations at the interfaces between integrated circuits (ICs) and the circuit assemblies with which the ICs communicate. More particularly, the present invention relates generally to the functional pathway configuration at the interface between one or more semiconductor integrated circuit dice, including an IC package and the circuitry of a system wherein the integrated circuit dice is a digital signal controller. Even more particularly, the present invention relates to a 18, 28, 40, 44, 64 or 80 pin functional pathway configuration for the interface between the digital signal controller and the system in which it is embedded.

Abstract: A processor that has pulse width modulation generation circuitry that provides an improved capability to deal with fault conditions, and particularly with multiple concurrent fault conditions, occurring in external circuitry and devices that are connected to PWM hardware included in a processor.

Abstract: An instruction set is provided that features ninety four instructions and various address modes to deliver a mixture of flexible micro-controller like instructions and specialized digital signal processor (DSP) instructions that execute from a single instruction stream.

Abstract: A processor has a native word width of multiples of a byte width. The processor may, nonetheless, process, store and retrieve data in word or byte widths depending on the mode of an instruction directing the processing. Instructions may assume either a word or a byte mode. In the word mode, the instruction causes the processor to read, store and operate on word width data. In the byte mode, the instruction causes the processor to read, store and operate on byte data where the byte is specified based on upper/lower byte bits in the instruction. This architecture permits a new generation of processor having word widths of more than one byte to be backward compatible with software written for byte width processors.

Abstract: An extended resolution mode for a PWM generator is provided. The extended resolution mode takes advantage of the higher frequency Q clock generation scheme on processors that include the PWM generator. Specifically, a Q clock counter, which operates at four times the frequency of the oscillator fed into the rest of the PWM generator, is used to generate a two bit output. This two bit output is used as the lower order bits of an n-bit period counter of the PWM generator during a high resolution mode to generate PWM signal edges. The two upper bits of the n-bit period counter are ignored during PWM signal edge generation in high resolution mode. The high resolution mode greatly improves PWM signal control at low frequencies of operation. During a normal resolution mode, the Q clock counter is ignored during PWM signal edge generation.

Abstract: A processor that has pulse width modulation generation circuitry that provides an improved capability to deal with fault conditions, and particularly with multiple concurrent fault conditions, occurring in external circuitry and devices that are connected to PWM hardware included in a processor.

Abstract: Configuration bits are provided that configure PWM outputs of a processor incorporating a PWM module. The configuration bits cause the PWM module to put the PWM outputs into tri-state, active high or active low modes when the PWM module is inactive or when individual PWM outputs are not enabled. The configuration bits are stored in non-volatile memory and perform the configuration after power-up of the processor and after a reset when the PWM module is generally in an inactive state.

Abstract: A processor that has pulse width modulation generation circuitry that provides an improved ability to deal with the less than perfect switching characteristics of external switching devices that are connected to PWM hardware included in a processor. Complementary PWM output signals have dual deadtime delay in which the delay between the inactivation of the first signal and the activation of the second signal may be different than the delay between the inactivation of the second signal and the activation of the first signal. This provides an improved capability to deal with non-symmetric switching characteristics of the external switching devices, and the circuitry to which they are connected.

Abstract: Compounds of general formula (I), wherein W represents a 5- or 6-membered aromatic heterocyclic ring containing one or more non-quaternised sp2 nitrogen atoms in its ring, which heterocyclic ring may be optionally fused to a benzene ring or to a further 5- or 6-membered aromatic heterocyclic ring containing one or more nitrogen atoms, wherein at least one of the said heterocyclic rings may also contain an oxygen or sulphur atom, and wherein any of the rings may be optionally substituted with one or more substituents selected from --C.sub.1 -C.sub.6 alkyl, --OC.sub.1 -C.sub.6 alkyl, halo, --CF.sub.3 and --CN; Z represents a) a divalent alkanediyl group from 1 to 8 carbon atoms which may be a straight or branched-chain, wherein the said group is either unsubstituted or substituted by one or more substituents selected from hydroxy, --OC.sub.1 -C.sub.6 alkyl, --SC.sub.1 -C.sub.

Abstract: Compounds of general formula I: ##STR1## wherein W represents imidazo [4,5-c]pyridin-1-yl, imidazo [4,5-c]pyridin-3-yl and imidazo [4,5-c]pyridin-5-yl optionally substituted with one or more --C.sub.1 -C.sub.6 alkyl substituents; Z represents a) a divalent alkanediyl, alkenediyl or alkynediyl group; b) a --(CH.sub.2).sub.q U(CH.sub.2).sub.r -- group, optionally substituted, wherein q is an integer from 0-3, r is an integer from 0-3 and U is --O-- or --S--; Q represents a carbonyl, thiocarbonyl or sulphonyl group; B represents a) a --VR.sup.8 group wherein V is --C(.dbd.O)O-- or --CH.sub.2 O--; are antagonists of platelet activating factor (PAF).

Abstract: The present invention is directed to compounds of general formula I as well their pharmaceutically and veterinarily acceptable acid addition salts or hydrates thereof. The present invention is further directed to pharmaceutical and veterinary compositions containing the compounds of general formula I. The present compounds of general formula I are antagonist of platelet activating factor (PAF). Accordingly, the present invention is also directed to methods for preventing, treating or ameliorating in human or mammalian animals, various diseases or physiological conditions mediated by PAF.

Abstract: Compounds of the general formula I; ##STR1## wherein: A.sup.1 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.1 --;A.sup.2 is --N.dbd., --CH.dbd. or --CR.sup.2 .dbd.;provided that, when one of A.sup.1 and A.sup.2 is a nitrogen atom, the other of A.sup.1 and A.sup.2 is other than a nitrogen atom;wherein the remainder of the variables are defined in the specification;and their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.

Abstract: The invention encompasses compounds of general formula I: ##STR1## wherein W represents an imidazo[4,5-c]pyridyl group, optionally substituted with one or more substituents selected from C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, halo, CF, and CN; and Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 are variables. These compounds are useful as antagonists of platelet activating factor.

Abstract: Compounds of general formula I; ##STR1## wherein: A.sup.1 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.1 --;A.sup.2 is --N.dbd., --CH.dbd. or --CR.sup.2 .dbd.;provided that, when one of A.sup.1 and A.sup.2 is a nitrogen atom, the other of A.sup.1 and A.sup.2 is other than a nitrogen atom; wherein the rest of the variables are defined in the specification; and their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment of amelioration of various diseases or disorders mediated by PAF.

Abstract: Compounds of general formula I; ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, A.sup.1, A.sup.2, B, and X are variables.These compounds are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.

Abstract: Compounds of general formula I; ##STR1## wherein: A.sup.1 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.1 --;A.sup.2 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.2 --;provided that, when one of A.sup.1 and A.sup.2 is a nitrogen atom, the other of A.sup.1 and A.sup.2 is other than a nitrogen atom; wherein the other variables are as defined in the specificationand their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.